What is the price target for CRDL stock?
8 analysts have analysed CRDL.CA and the average price target is 9.59 CAD. This implies a price increase of 526.67% is expected in the next year compared to the current price of 1.53.
CARDIOL THERAPEUTICS INC-A (CRDL.CA) Forecast, Price Target & Analyst Ratings
TSX:CRDL • CA14161Y2006
Current stock price
1.53 CAD
+0.03 (+2%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARDIOL THERAPEUTICS INC-A (CRDL.CA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -CA$0.08
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
CA$9.59
Upside
+ 526.67%
From current price of CA$1.53 to mean target of CA$9.59, Based on 8 analyst forecasts
Low
CA$7.88
Median
CA$9.59
High
CA$11.55
Price Target Revisions
1 Month
0.00%
3 Months
-3.59%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for CRDL.CA. The average price target is 9.59 CAD. This implies a price increase of 526.67% is expected in the next year compared to the current price of 1.53.
The average price target has been revised downward by 3.59% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
CRDL.CA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CRDL.CA.
In the previous month the buy percentage consensus was at a similar level.
CRDL.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-08 | Raymond James Capital | Downgrade | Market Perform |
| 2022-09-01 | Raymond James Capital | Downgrade | Market Perform |
| 2022-04-18 | Canaccord Capital | Reiterate | Buy |
| 2022-03-17 | Raymond James Capital | Downgrade | Market Perform |
| 2022-02-04 | Raymond James Financial | Initiate | Outperform |
| 2021-11-11 | RaymondJamesFinancial | Initiate | Outperform |
| 2021-08-25 | Raymond James Financial | Upgrade | Outperform |
| 2021-05-19 | ATB Catpital | Downgrade | Speculative Buy |
| 2021-05-19 | ATB Capital | Downgrade | |
| 2021-05-17 | Raymond James Financial | Upgrade | Outperform |
| 2021-04-29 | Raymond James Financial | Upgrade | Market Perform -> Outperform |
| 2021-04-14 | Raymond James Financial | Reiterate | Market Perform |
| 2021-04-05 | ATB Capital | Downgrade | Speculative Buy |
| 2021-03-04 | Raymond James Financial | Initiate | Market Perform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -CA$0.08
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 9.33%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CRDL.CA is expected to report earnings on 4/1/2026. The consensus EPS estimate for the next earnings is -0.08 CAD and the consensus revenue estimate is 0 CAD.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 80K | -100.00% | 12.99M | 52.313M 302.72% | 115.49M 120.77% | 251.32M 117.61% | 357.1M 42.09% | 525.31M 47.10% | 678.83M 29.22% | |||||||
| EBITDA YoY % growth | -13.98M -99.43% | -20.46M -46.35% | -38.44M -87.88% | -24.48M -6.97% | -23.46M 28.17% | -32.773M -35.10% | -30.806M 22.80% | -24.012M 22.05% | -21.18M 11.79% | -21.581M -1.89% | 10.839M 150.22% | 58.904M 443.44% | 158.39M 168.90% | 260.36M 64.38% | 309.83M 19.00% | |
| EBIT YoY % growth | -14.13M -99.01% | -20.69M -46.43% | -38.66M -86.85% | -39.79M -6.93% | -29.07M 27.95% | -40.494M -35.22% | -36.006M 10.60% | -31.81M 11.65% | -15.975M 49.78% | 18.378M 215.05% | 81.066M 341.10% | 186.85M 130.49% | 222.94M 19.31% | 315.08M 41.33% | 372.95M 18.37% | |
| Operating Margin | N/A | N/A | -48,325.00% | N/A | N/A | N/A | N/A | N/A | -122.98% | 35.13% | 70.19% | 74.35% | 62.43% | 59.98% | 54.94% | |
| EPS YoY % growth | N/A | N/A 12.54% | N/A -10.14% | -0.54 8.50% | -0.44 10.20% | -0.55 -15.91% | -0.40 22.00% | -0.57 -42.74% | -0.16 72.46% | 0.08 149.17% | 0.51 564.72% | 1.31 155.91% | 1.03 -21.07% | 1.69 64.08% | 2.03 19.52% |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 9.33% | -0.11 -12.20% | -0.11 -12.20% | -0.11 6.50% | -0.11 -37.50% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.506M -5.17% | -9.894M -17.38% | -10.2M -32.88% | -10.71M -5.21% | -11.322M -7.77% |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.19%
EPS Next 5 Year
24.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
13.88%
EBIT Next 5 Year
17.79%
CARDIOL THERAPEUTICS INC-A / CRDL.CA Forecast FAQ
When does CARDIOL THERAPEUTICS INC-A (CRDL.CA) report earnings?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) will report earnings on 2026-04-01, after the market close.
Can you provide the consensus estimates for CARDIOL THERAPEUTICS INC-A next earnings?
The consensus EPS estimate for the next earnings of CARDIOL THERAPEUTICS INC-A (CRDL.CA) is -0.08 CAD and the consensus revenue estimate is 0 CAD.
What is the consensus rating for CRDL stock?
The consensus rating for CARDIOL THERAPEUTICS INC-A (CRDL.CA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.